CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Bruns Ingmar Chief Medical Officer | Grant or award | +9,727 | $2.18 | $21K | 43,059 |
| 2026-02-09 | Bruns Ingmar Chief Medical Officer | Sale | −335 | $2.39 | $802 | 33,332 |
| 2026-02-06 | Bruns Ingmar Chief Medical Officer | Sale | −2,962 | $2.43 | $7K | 33,667 |
| 2026-01-08 | Bruns Ingmar Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +365,000 | 365,000 | ||
| 2025-02-06 | Bruns Ingmar Chief Medical Officer | Purchase | +20,000 | $2.28 | $46K | 36,629 |
| 2025-02-03 | Bruns Ingmar Chief Medical Officer | Grant or award | +16,629 | 16,629 | ||
| 2025-02-03 | Bruns Ingmar Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +16,629 | 16,629 | ||
| 2024-12-02 | Bruns Ingmar Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +712,650 | 712,650 |
Page 1 of 1 · 8 trades